IGFBP-2 vaccine to prevent ovarian cancer return
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a vaccine that targets a protein called IGFBP-2 to prevent ovarian cancer from coming back. It is for people whose CA-125 blood test shows the cancer might be returning, but who don't yet have tumors visible on scans.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had ovarian, fallopian tube, or primary peritoneal cancer and received chemotherapy with a platinum drug.
- Your CA-125 blood test has gone up to at least twice the normal level or twice your lowest level after the most recent treatment.
- You do not have any tumors that can be seen on a CT scan (fluid in the belly or around the lungs is okay if you don't have symptoms).
- You are at least 18 years old, have a life expectancy of at least 3 months, and are in good enough health to be up and about (ECOG score 0-1).
- Your blood counts, kidney function, and liver function are within certain safe limits, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies a maintenance vaccine (DCVAC/OvCa) given after standard first-line chemotherapy and surgery for certain advanced ovarian cancers. It aims to help keep the cancer from coming back for longer by boosting the body’s anti-cancer response.
This trial tests combining surgery with an immunotherapy drug (sintilimab) for women whose ovarian cancer has returned after initial treatment. It aims to see if this approach can improve outcomes for people with specific tumor markers.
This trial tests if removing the fallopian tubes (fimbriectomy) can lower the risk of ovarian or pelvic cancer in women with certain gene mutations. The goal is to find a less invasive prevention option.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
This trial tests a new drug called IMNN-001 combined with standard chemotherapy for women with advanced ovarian, fallopian tube, or peritoneal cancer. The goal is to see if adding this drug can improve safety and effectiveness.
This Phase 1/2 trial tests a new cancer vaccine therapy combined with pembrolizumab (an immunotherapy) to treat advanced, recurrent ovarian, fallopian tube, or primary peritoneal cancer. It may help your immune system recognize and attack the cancer, especially if your tumor has a specific target called FRα.
Hear when a new Fallopian Tube Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.